

Global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

<https://marketpublishers.com/r/GB5FAA822A2EN.html>

Date: November 2017

Pages: 210

Price: US\$ 4,400.00 (Single User License)

ID: GB5FAA822A2EN

Abstracts

Attention Deficit Hyperactivity Treatment Disorder

Attention deficit hyperactivity disorder is one of the most common brain disorder characterized by impairing and pervasive symptoms of hyperactivity, inattention, and impulsivity. It is commonly observed in children (

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET INTRODUCTION

2.1. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Taxonomy

2.2. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market -Definitions

2.2.1. Drug Class

2.2.2. Age Group

2.2.3. Distribution Channel

3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Factors Impact Analysis

3.6. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Product Innovations

4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Oppurtunity Analysis

5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD) MARKET, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Stimulants

5.1.1. Amphetamines

5.1.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)

5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.1.3. Market Opportunity Analysis

5.1.2. Methylphenidate

5.1.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)

5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.2.3. Market Opportunity Analysis

5.1.3. Dextroamphetamine

5.1.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)

5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.3. Market Opportunity Analysis

5.1.4. Dexmethylphenidate

5.1.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)

5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.4.3. Market Opportunity Analysis

5.2. Non-Stimulants

5.2.1. Atomoxetine

5.2.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)

5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.1.3. Market Opportunity Analysis

5.2.2. Bupropion

5.2.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)

5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.2.3. Market Opportunity Analysis

5.2.3. Guanfacine

5.2.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)

5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.3.3. Market Opportunity Analysis

6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD) MARKET FORECAST, BY AGE GROUP, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Paediatric

- 6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
- 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 6.1.3. Market Opportunity Analysis

6.2. Adolescent

- 6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
- 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 6.2.3. Market Opportunity Analysis

6.3. Adults

- 6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
- 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 6.3.3. Market Opportunity Analysis

7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD) MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Retail Pharmacies

- 7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
- 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.1.3. Market Opportunity Analysis

7.2. Hospital Pharmacies

- 7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
- 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.2.3. Market Opportunity Analysis

7.3. Online Pharmacies

- 7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
- 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.3.3. Market Opportunity Analysis

7.4. Specialty Clinics

- 7.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
- 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.4.3. Market Opportunity Analysis

8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD) MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America

- 8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.1.3. Market Opportunity Analysis
- 8.2. Europe
 - 8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
 - 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 8.2.3. Market Opportunity Analysis
- 8.3. Asia-Pacific
 - 8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
 - 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 8.3.3. Market Opportunity Analysis
- 8.4. Latin America
 - 8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
 - 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 8.4.3. Market Opportunity Analysis
- 8.5. Middle East and Africa
 - 8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
 - 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 8.5.3. Market Opportunity Analysis
- 8.6. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type, Age Group, Distribution Channel and Region, 2017 - 2023

9. NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 9.1. Drug Class Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 9.1.1. Stimulants
 - 9.1.1.1. Amphetamines
 - 9.1.1.2. Methylphenidate
 - 9.1.1.3. Dextroamphetamine
 - 9.1.1.4. Dexmethylphenidate
 - 9.1.2. Non-Stimulants
 - 9.1.2.1. Atomoxetine
 - 9.1.2.2. Bupropion
 - 9.1.2.3. Guanfacine
 - 9.1.2.4. Others
- 9.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD

Mn), Y-o-Y Growth (%) and Market Share (%)

9.2.1. Paediatric

9.2.2. Adolescent

9.2.3. Adults

9.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.3.1. Hospital Pharmacies

9.3.2. Specialty Clinics

9.3.3. Retail Pharmacies

9.3.4. Online Pharmacies

9.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

9.5. North America Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel, and Country, 2017 - 2023

9.6. North America Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends

10. EUROPE ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Drug Class Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1. Stimulants

10.1.1.1. Amphetamines

10.1.1.2. Methylphenidate

10.1.1.3. Dextroamphetamine

10.1.1.4. Dexmethylphenidate

10.1.2. Non-Stimulants

10.1.2.1. Atomoxetine

10.1.2.2. Bupropion

10.1.2.3. Guanfacine

10.1.2.4. Others

10.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Paediatric

10.2.2. Adolescent

10.2.3. Adults

10.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Hospital Pharmacies

10.3.2. Specialty Clinics

10.3.3. Retail Pharmacies

10.3.4. Online Pharmacies

10.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.4.1. Germany

10.4.2. UK

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Poland

10.4.8. Rest of Europe

10.5. Europe Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel, and Country, 2017 - 2023

10.6. Europe Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends

11. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Drug Class Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. Stimulants

11.1.1.1. Amphetamines

11.1.1.2. Methylphenidate

11.1.1.3. Dextroamphetamine

11.1.1.4. Dexmethylphenidate

11.1.2. Non-Stimulants

11.1.2.1. Atomoxetine

11.1.2.2. Bupropion

11.1.2.3. Guanfacine

11.1.2.4. Others

11.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD

Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Paediatric

11.2.2. Adolescent

11.2.3. Adults

11.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Hospital Pharmacies

11.3.2. Specialty Clinics

11.3.3. Retail Pharmacies

11.3.4. Online Pharmacies

11.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. ASEAN

11.4.5. Australia & New Zealand

11.4.6. Rest of Asia-Pacific

11.5. Asia-Pacific Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel, and Country, 2017 - 2023

11.6. Europe Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends

12. LATIN AMERICA ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Stimulants

12.1.1.1. Amphetamines

12.1.1.2. Methylphenidate

12.1.1.3. Dextroamphetamine

12.1.1.4. Dexmethylphenidate

12.1.2. Non-Stimulants

12.1.2.1. Atomoxetine

12.1.2.2. Bupropion

12.1.2.3. Guanfacine

12.1.2.4. Others

12.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD

Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Paediatric

12.2.2. Adolescent

12.2.3. Adults

12.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Hospital Pharmacies

12.3.2. Specialty Clinics

12.3.3. Retail Pharmacies

12.3.4. Online Pharmacies

12.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Argentina

12.4.4. Venezuela

12.4.5. Rest of Latin America

12.5. Latin America Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel, and Country, 2017 - 2023

12.6. Latin America Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends

13. MIDDLE EAST AND AFRICA ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1.1. Stimulants

13.1.1.1. Amphetamines

13.1.1.2. Methylphenidate

13.1.1.3. Dextroamphetamine

13.1.1.4. Dexmethylphenidate

13.1.2. Non-Stimulants

13.1.2.1. Atomoxetine

13.1.2.2. Bupropion

13.1.2.3. Guanfacine

13.1.2.4. Others

13.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 13.2.1. Paediatric
- 13.2.2. Adolescent
- 13.2.3. Adults
- 13.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.3.1. Hospital Pharmacies
 - 13.3.2. Specialty Clinics
 - 13.3.3. Retail Pharmacies
 - 13.3.4. Online Pharmacies
- 13.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.4.1. Brazil
 - 13.4.2. Mexico
 - 13.4.3. Argentina
 - 13.4.4. Venezuela
 - 13.4.5. Rest of Latin America
- 13.5. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 13.5.1. Gulf Cooperation Council (GCC) Countries
 - 13.5.2. Israel
 - 13.5.3. South Africa
 - 13.5.4. Rest of MEA
- 13.6. MEA Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel and Country, 2017 - 2023
- 13.7. MEA Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends

14. COMPETITION LANDSCAPE

- 14.1. Strategic Dashboard of Top Market Players
- 14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
 - 14.2.1. Allergan, Inc. (U.S.)
 - 14.2.2. Medtronic. (Covidien PLC) (U.S.)
 - 14.2.3. EnteroMedics, Inc (U.S.)
 - 14.2.4. Cousin Biotech (France)
 - 14.2.5. Surgical IOC (Peters Surgical SAS) (France)
 - 14.2.6. PARE Surgical Inc. (U.S.)

14.2.7. GI Dynamics (U.S.)

15. RESEARCH METHODOLOGY

Key Assumptions and Acronyms

I would like to order

Product name: Global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/GB5FAA822A2EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB5FAA822A2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970